Clinical Trials Sponsored by Research & Development Institute, Inc.

Total 2446 results

National Development and Research Institutes, Inc.

Unknown

Mobile Intervention for Young Opioid Users

Opioid-Related Disorders

United States
National Development and Research Institutes, Inc.

Unknown

Applying Web Technology to Buprenorphine Treatment

Adult Opioid-Dependence

United States
Criterium, Inc.
EMD Serono Research & Development Institute, Inc.

Terminated

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Advanced Non-Small Cell Lung Cancer With MET Mutations

United States
Primex Clinical Laboratories, Inc.
Research & Development Institute, Inc.

Unknown

Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics

Patients on Medications Metabolized Via CYP450

United States
National Development and Research Institutes, Inc.

Unknown

The Staying Safe Intervention (Ssafe)

Hepatitis C | Opioid Use

United States
National Development and Research Institutes, Inc.

Unknown

Increasing HIV Testing in Urban Emergency Departments Via Mobile Technology

HIV Testing

United States
Centocor Research & Development, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (PHOENIX1)

Psoriasis

United States, Belgium, Canada
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer

United States, United Kingdom, Belgium, Russian Federation
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous
EMD Serono Research & Development Institute, Inc.

Recruiting

The MS-LINK™ Outcomes Study

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.

Completed

Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)

Multiple Sclerosis

Lebanon, United States, Turkey, Sweden, Finland, France, Thailand, Serbia, Italy, United Kingdom, United Arab Emirates, Bulgaria, Belgium, Estonia, Argentina, Austria, Bosnia and Herzegovina, Canada, Croatia, Czechia, Georgia, Ger... and more
EMD Serono Research & Development Institute, Inc.

Recruiting

Next-Gen MS: Feed-forward PRO Data for MS Research

Multiple Sclerosis (MS)

United States
EMD Serono Research & Development Institute, Inc.

Completed

Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)

Carcinoma, Merkel Cell

United States, Spain, Australia, Italy, Germany, France, Japan
EMD Serono Research & Development Institute, Inc.

Completed

CLARITY Extension Study

Relapsing-Remitting Multiple Sclerosis

Croatia, United States, Bulgaria, France, Italy, Russian Federation, Turkey, United Kingdom, Estonia, Germany, Latvia, Lithuania, Poland, Austria, Brazil, Canada, Finland, Portugal, Greece, Serbia, Denmark, Ukraine, Saudi Arabia, Lebanon and more
EMD Serono Research & Development Institute, Inc.

Completed

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (ONWARD)

Multiple Sclerosis

United States, Italy, Russian Federation, Spain
Rowan University
National Development and Research Institutes, Inc.

Completed

Incentives for Internet-based Adherence to SMBG for Teens With T1D

Contingent Versus Noncontingent Incentives
Janssen Research & Development, LLC
Innovaderm Research Inc.

Completed

Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling

Psoriasis Vulgaris

Canada
Cipherome, Inc.
DHR Health Institute for Research and Development

Completed

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics (CARES2)

Myocardial Infarction | Ischemic Stroke | Thrombosis | Bleeding | Stent Thrombosis

United States
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Unknown

Mobile Psychosocial Interventions for MMT Clients (MobileMMT)

Substance Abuse | Opioid Abuse

United States
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Unknown

Transmission Reduction Intervention Project (TRIP)

HIV

United States, Greece, Ukraine
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Unknown

Comparative Effectiveness of Web-based Versus Traditional Adolescent HIV Prevention

HIV Infections | Hepatitis | Sexually Transmitted Infections

United States
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Colorado Women's TC Project

Substance-Related Disorders

United States
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Re-Entry MTC for Offenders With MICA Disorders

Substance-Related Disorders | Mental Disorders

United States
VA Office of Research and Development
Regenstrief Institute, Inc.

Completed

Evaluation of VLER-Indiana Health Information Exchange Demonstration Project (VLER-IHIE)

Cardiovascular Diseases | Heart Failure | Diabetes Mellitus | Asthma | Osteoporosis

United States
National Institute on Drug Abuse (NIDA)
National Development and Research Institutes, Inc.

Completed

Effectiveness of Self-Help for Dually-Diagnosed Persons - 1

Substance-Related Disorders | Mental Disorders | Dual Diagnosis

United States
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Technological Innovations in Behavioral Treatments for Cigarette Smoking

Cigarette Smoking

United States
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Internet-based Group Contingency Management to Promote Smoking Abstinence

Cigarette Smoking

United States
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)

Completed

HIV Prevention Intervention for Couples

Acquired Immunodeficiency Syndrome

United States
Kansas State University
National Development and Research Institutes, Inc.

Completed

Army Training at High Intensity Study (ATHIS)

Obesity

United States
BioNTech Research & Development, Inc.

Recruiting

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Pancreatic Cancer

United States
Janssen Research & Development, LLC
Eisai Inc.

Completed

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux

United States, United Kingdom, Poland, Germany
University Hospital, Montpellier
National Development and Research Institutes, Inc.

Active, not recruiting

Measure of the Potential Evoked by Electric Stimulation (PE&CE)

Low Grade Glioma of Brain

France
Janssen Research & Development, LLC
Genentech, Inc.

Completed

A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX)

Carcinoma, Non-Small-Cell Lung

France, United States, Spain, Hungary, Poland
Janssen Research & Development, LLC
Eisai Inc.

Completed

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Gastroesophageal Reflux Disease (GERD)

United States, Poland, United Kingdom, Belgium, Brazil
Kansas State University
National Development and Research Institutes, Inc.

Completed

The First 20 Fire Academy Recruits Exercise Training Program

Physical Fitness

United States
BioNTech Research & Development, Inc.

Terminated

Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy

Pancreatic Carcinoma | Tumors That Express CA 19-9

United States
Columbia University
Centocor Research & Development, Inc.

Completed

Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients

Lupus Nephritis

United States
Syracuse VA Medical Center
National Development and Research Institutes, Inc.

Completed

Peer Supported Web-based CBT for OEF/OIF Veterans With PTSD and Substance Misuse

Substance Use Disorders | Stress Disorders, Post-traumatic

United States
Embry-Riddle Aeronautical University
National Development and Research Institutes, Inc.

Recruiting

EaseAlert: Tactile Firefighter Alerting System

Sleep | Heart Rate | Sleep Habit

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Participants With Advanced Malignancies

Neoplasms

France, Belgium
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Glaucoma Research & Education Group
PharmaLogic Development, Inc.

Unknown

The Efficacy of Selective Laser Trabeculoplasty

Primary Open Angle Glaucoma | Ocular Hypertension | Pigment Dispersion Glaucoma | Pseudo-Exfoliative Glaucoma

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE)

Leukemia, Myeloid, Acute

Switzerland, Israel, Spain, France, Turkey, Italy, Australia, Brazil, Russian Federation
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

Leukemia, Myeloid, Acute

Canada, United States, Poland, Switzerland, Germany
Glaucoma Research & Education Group
PharmaLogic Development, Inc.

Completed

Effectiveness of a Procedure for Previously Failed Glaucoma Surgery

Glaucoma

United States
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
Zona Health, Inc
Research & Development Concierge Company

Terminated

A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients

Hypertension, Systolic

United States
ChemRar Research and Development Institute, LLC

Not yet recruiting

A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

Anxiety Disorder Generalized
ChemRar Research and Development Institute, LLC

Completed

А Dose-finding Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

Anxiety Disorder Generalized

Russian Federation

Clinical Trials Sponsored by Research & Development Institute, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations